

## References

- Munra S, Christophe-Stine L. Pregnancy in myositis and scleroderma. *Best Pract Res Clin Obstet Gynaecol.* 2019; <http://dx.doi.org/10.1016/j.bpobgyn.2019.10.004>.
- Che WG, Hellgren K, Septhansson O, Lundberg IE, Holmqvist M. Pregnancy outcomes in women with idiopathic inflammatory myopathy, before and after diagnosis—a population-based study. *Rheumatology.* 2020;59:2572–80.
- United Nations Statistics Division. Geographic regions. USA, New York; 2020. <https://unstats.un.org/unsd/methodology/m49/> [accessed 30.12.20].
- Iba-Ba J, Mayi-Tsonga S, Bignoumba IR, Diallo T, Kombila M, Coniquet S, et al. Dermatomyosite et grossesse: une observation au Gabon. *Med Trop.* 2009;69:603–5.
- Kaddour N, Marzouk S, Frigui M, Chaabouni Y, Maazoun F, Ben Salah R, et al. Grossesse au cours des dermatomyosites et polymyosites. *Rev Méd Intern.* 2009;30:S97.
- Ousmane C, Makhtar BEH, Fatoumata B, Massi GD, Lémine DSM, Soda DSM, et al. Polymyositis and anti-SRP antibodies and pregnancy about 2 cases. *PAMJ.* 2016;24:192.
- Awatef K, Salim G, Zahra MF. A rare case of dermatomyositis revealed during pregnancy with good outcome. *PAMJ.* 2016;23:117.
- Cisse L, Karabinta Y. Neonatal lupus in an infant of a mother followed up for dermatomyositis: medical images. *PAMJ.* 2018;31:117.
- Iba Ba J, Nseng N, Ntsame N, Igalá M, Kombila U, Malekou M, et al. Grossesses au cours de maladies auto-immunes en zone subsaharienne à travers l'expérience du service de médecine du CHU de Libreville. *Médecine Santé Trop.* 2019;29:206–12.

Mickael Essouma<sup>a,b,\*</sup> Jean Jacques Noubiap<sup>c</sup><sup>a</sup> Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon<sup>b</sup> Network of Immunity in Infections, Autoimmunity and Malignancy (NIIMA), Universal Scientific Education and Research Network (USERN), Yaoundé, Cameroon<sup>c</sup> Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia

\* Corresponding author.

E-mail address: [essmic@rocketmail.com](mailto:essmic@rocketmail.com) (M. Essouma).<https://doi.org/10.1016/j.reuma.2021.04.005>

1699–258X/ © 2021 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

### The Value of a Negative Antinuclear Antibody (ANA) Test: An Often Forgotten Result




#### El valor de una prueba de anticuerpos antinucleares (ANA) negativa: un resultado a menudo olvidado

Dear Editor:

It is quite clear that medicine is biased towards positive results and the same applies to the practice of pathology.<sup>1</sup> One of the ubiquitous tests in autoimmunity, the antinuclear antibody (ANA) suffers from this very same fate. A number of guidelines report on the clinical utility of a positive ANA and dissuade clinicians from requesting this test in the setting of low pre-test probability

for an ANA-associated autoimmune disorder (AAD).<sup>2</sup> This is certainly sound advice and prevents unnecessary investigations and healthcare expenditure. Yet, it is important to realise the clinical importance and pitfalls of a negative ANA results which sometimes becomes forgotten.

The internationally-accepted “gold standard” to measure ANA is via indirect immunofluorescence on HEP-2 cells.<sup>3</sup> A negative ANA test on HEP-2 substrate usually means that there is no significant detection of IgG ANA (in the nucleus) at a specified dilution of serum – usually 1:80 to 1:160. There is a move to also classify positive cytoplasmic and mitotic staining of the HEP-2 substrate as ANA positive.<sup>3,4</sup> This may improve the sensitivity of detecting AADs and prompt appropriate further testing and follow-up (Fig. 1).<sup>3</sup>



**Fig. 1.** Example cytoplasmic staining on the HEP-2 substrate. (A) F-actin staining suggesting the presence of smooth muscle antibodies found in autoimmune hepatitis and related disorders. (B) Coarse, granular cytoplasmic staining suggestive of anti-mitochondrial antibodies found in primary biliary cirrhosis. (C) Smooth, homogenous cytoplasmic staining suggestive of anti-ribosomal P antibodies found in systemic lupus erythematosus. (D) Large cytoplasmic dots staining suggestive of anti-GW bodies. All micrographs are taken at a magnification of 400×.

The high sensitivity and negative predictive value (NPV) for systemic lupus erythematosus (SLE) makes the ANA test a good “rule out” test to essentially exclude this disorder if it is negative.<sup>5</sup> Indeed, the most recent European League Against Rheumatism/American College of Rheumatology guidelines for the diagnosis of SLE mandates a positive ANA ( $\geq 1:80$ ) on the HEp-2 substrate to be considered for this diagnosis.<sup>6</sup> Sensitivities for detecting other AADs is low-moderate at best; yet also demonstrates very high NPVs.<sup>7</sup> Unless there has been a significant change in clinical picture or there is a suspicion of a laboratory issue, there is little value in repeating an ANA that is initially negative.<sup>8</sup>

A pitfall is that ANA is a screening test and may, in rare instances, miss low-level specific autoantibodies/anti-extractable nuclear antigens (ENAs) if more sensitive assays are not performed,<sup>9</sup> or miss anti-ENA that do not produce a characteristic ANA pattern e.g., anti-Ro52. Therefore, the substrate should be specified in the report since substrates such as the HEp-2000® (ImmunoConcepts) which has transfected Ro60 increase the detection of anti-Ro60 and hence, a negative result makes the presence of anti-Ro60 less likely.<sup>10</sup>

If there is a high clinical suspicion for an AAD, the clinician should request further anti-ENA tests and the overall clinical picture and physician's interpretation of the patient should prevail. This is especially of importance since commercial HEp-2 substrates, whilst generally demonstrating excellent inter-assay and inter-laboratory agreement, display subtle staining differences that affect the microscopist's final interpretation.<sup>11</sup> The significance of low levels of anti-ENA with negative ANA is not well established.

To conclude, clinicians should be aware of the value, implications and pitfalls of a negative ANA result when considering AADs. They should also be aware of their laboratory's definitions of a “negative” ANA result, the substrate used and whether they report non-nuclear patterns which may have important implications for their patients. Importantly, the overall clinical picture of the patient should be taken into considerations when deciding on the relevance of a negative ANA test.

## Funding

Nil.

## Conflict of interests

None declared.

## References

1. Vawdrey DK, Hripscak G. Publication bias in clinical trials of electronic health records. *J Biomed Inform.* 2013;46:139–41.
2. Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. *Arthritis Rheum.* 2002;47:434–44.
3. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. *Ann Rheum Dis.* 2014;73:17–23.
4. Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. *Ann Rheum Dis.* 2019;78:879–89.
5. Leuchten N, Hoyer A, Brinks R, Schoels M, Schneider M, Smolen J, et al. Performance of antinuclear antibodies for classifying systemic lupus erythematosus: a systematic literature review and meta-regression of diagnostic data. *Arthritis Care Res.* 2018;70:428–38.
6. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann Rheum Dis.* 2019;78:1151–9.
7. Slater CA, Davis RB, Shmerling RH. Antinuclear antibody testing: a study of clinical utility. *Arch Intern Med.* 1996;156:1421–5.
8. Lee AYS, Hudspeth AR, Adelstein S. The concordance of serial ANA tests in an Australian tertiary hospital pathology laboratory. *Pathology.* 2016;48:597–601.
9. Lee AYS, Beroukas D, Brown L, Lucchesi C, Kaur A, Gyedu L, et al. Identification of a unique anti-Ro60 subset with restricted serological and molecular profiles. *Clin Exp Immunol.* 2021;203:13–21.
10. Lee AYS, Beroukas D, Roberts-Thomson PJ. Utility of the HEp-2000 antinuclear antibody substrate. *Ann Rheum Dis.* 2020;79:e67.
11. Copple SS, Giles SR, Jaskowski TD, Gardiner AE, Wilson AM, Hill HR. Screening for IgG antinuclear autoantibodies by HEp-2 indirect fluorescent antibody assays and the need for standardization. *Am J Clin Pathol.* 2012;137:825–30.

Adrian Y.S. Lee <sup>a,b</sup>

<sup>a</sup> ICPMR & Department of Immunology, Westmead Hospital, Westmead, NSW, Australia

<sup>b</sup> Westmead Clinical School, The University of Sydney, Westmead, NSW, Australia

E-mail address: [adrian.lee1@health.nsw.gov.au](mailto:adrian.lee1@health.nsw.gov.au)

<https://doi.org/10.1016/j.reuma.2021.04.002>

1699-258X/ © 2021 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

## How do Spanish Rheumatologists handle referral? Survey of knowledge and approach before and after a training workshop<sup>☆</sup>



### ¿Cómo manejan la remisión los reumatólogos españoles? Encuesta de conocimientos y abordaje antes y después de un taller formativo

Dear Editor,

The aim of rheumatoid arthritis (RA) treatment is to achieve remission, but the criteria by which to establish remission are varied, complex, and unequally stringent<sup>1</sup>, with the consequent complication of management. The main criteria are the cut-off

points of composite indices (DAS28, SDAI, or CDAI), Boolean ACR/EULAR criteria, remission without treatment, or ultrasound remission<sup>2</sup>. Once remission is achieved, guidelines recommend dose reduction without discontinuing any drug (ACR<sup>3</sup>), tapering glucocorticoids initially and then biologic therapy (EULAR<sup>1</sup>), or tapering glucocorticoids (not classic DMARDs) and establishing a biologic therapy dose reduction plan (SER<sup>4</sup>).

Two years ago, we set out to analyse rheumatologists' knowledge regarding RA remission and its influence on therapeutic management in the outpatient setting. The rheumatologists completed a two-fold survey (Appendix B. Supplementary Material) before and 3 months after attending four scientific workshops on remission and management of patients in remission (including the RedoSER tool)<sup>5</sup>. Respondents were deemed to have elevated knowledge when  $\geq 70\%$  answered correctly; a 10-point increase or decrease in correct answers before and after the workshop implied variation.

<sup>☆</sup> Please cite this article as: Balsa A, González-Álvaro I, Sanmartí R, Corominas H. ¿Cómo manejan la remisión los reumatólogos españoles? Encuesta de conocimientos y abordaje antes y después de un taller formativo. *Reumatol Clin.* 2022;18:564–566.